An interventional study of NobleStitch™EL Suture Mediated Closure System and Amplatzer PFO Occluder in Foramen Ovale, Patent and Stroke, Ischemic, sponsored by Nobles Medical Technologies II Inc. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-03-23.
Sponsored by Nobles Medical Technologies II Inc · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Foramen Ovale, Patent with a site in United States — 10 open to participants now, 12 under way, 1 of them phase 3. Foramen Ovale, Patent · United States.
Among the 36 studies in Foramen Ovale, Patent with a site in United States, this one is the 5th largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2021, is one of 15 with no phase, reaches primary completion later than 4 of the 11 other live ones, and was the 25th registered.
137 studies on the registry are indexed under Foramen Ovale, Patent; 47 are open to participants now.
Browse Foramen Ovale, Patent studies →10 of the 36 studies in Foramen Ovale, Patent with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 18–55
Tufts Medical Center · Sites in United States
Ages 18+
Scripps Health · Sites in United States
Ages 18+
Recross Cardio, Inc. · Sites in United States
Ages 18–65
Abbott Medical Devices · Sites in United States, Denmark, Estonia and 7 more countries
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Foramen Ovale, Patent studies recruiting now, 11 (32%) set no upper age limit and 19 (56%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 6 · Phase 4 1
First in 1993; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 640 is above the median of 154 across 69 interventional studies indexed under Foramen Ovale, Patent.
Median enrollment 168 across the 25 interventional studies, 256 across the 11 observational. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 36 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Nobles Medical Technologies II Inc as lead sponsor.
Nobles Medical Technologies II Inc has 1 study filed under Foramen Ovale, Patent — fewer than ten, so there is no comparison to draw.
3 of the studies in Foramen Ovale, Patent with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04339699Nobles Medical Technologies II IncNobleStitch EL STITCH Trial is a PFO Comparative Trial | 2026-12-31 |
| NCT07420400Scripps HealthNon-Invasive Detection of Right-to-Left Cardiac Shunts | 2027-01-01 |
| NCT07172464Recross Cardio, Inc.Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies in Foramen Ovale, Patent with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
STITCH - Prospective Multi-Center Comparative Parallel Concurrent Study of the NobleStitch™ EL versus FDA-approved Amplatzer Occluder device for closure of Patent Foramen Ovale to prevent recurrent Ischemic stroke.
To demonstrate the non-inferiority of the NobleStitch™ EL with medical management in both safety and effectiveness compared to the FDA-approved Amplatzer Occluder with medical management for PFO Closure.
To demonstrate that the NobleStitch EL does not increase the incidence of ischemic stroke compared to published medical management data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Stroke is defined as an acute focal neurological deficit, presumed to be due to focal ischemia, and either:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants treated with the NobleStitch™EL device
Device: NobleStitch™EL Suture Mediated Closure System
Participants treated with the Amplatzer PFO Occluder device
Device: Amplatzer PFO Occluder
Percutaneous closure of Patent Foramen Ovale (PFO) using NobleStitch™EL suture Medicate Closure System
Percutaneous closure of Patent Foramen Ovale (PFO) using Amplatzer PFO Occluder
Effective PFO closure rate of the NobleStitch EL
Effectiveness PFO closure rate of NobleStitch EL suture mediated closure with medical management compared to Amplatzer PFO occluder with medical management for PFO closure. Effective PFO closure rate defined as Grade 0 or 1 shunt at rest and during Valsalva at 6 month post closure attempts
Time frame: 6 months
Decreased event rate of recurrent ischemic stroke following PFO closure using NobleStitch EL
Safety of NobleStitch EL suture mediated closure system as compared to Amplatzer PFO Occluder Procedural and device related adverse event rate at 6 month follow up recurrent ischemic stroke through 5 years follow up
Time frame: 5 years
The occurrence of recurrent ischemic stroke post procedural of patent foramen ovale closure
Examination of Recurrent Ischemic Stroke through 5 year follow up. Comparison of the rate of Stroke associated with the NobleStitch EL procedure to that expected with medical management
Time frame: 5 Years
Plan to share: Yes — Individual participant data (IPD) from the completed STITCH clinical trial that underlie the results reported in the Study, shall after deidentification (text, tables, figures, and appendices).
Supporting information: Study protocol
Time frame: Immediately the following publication and ending 24 months after publication
Access criteria: Will be available to Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose. It will be available for Individual participant data meta-analysis
Started Jan 2021 (actual). Primary completion is estimated for Dec 2026, 71 months after the start.
Of 31 interventional studies with no phase under Foramen Ovale, Patent, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 100. This study's planned 71 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.